Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 4/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20618744 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2GAATSHR | |
| SCHEMBL20601429 | 0.93 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2GAATSHR | |
| SCHEMBL20618746 | 0.92 | KDM4E (0.54) | KDM4EGAACCR1ITGB3ITGA2B | |
| SCHEMBL20601245 | 0.91 | CCR1 (0.49) | KDM4EALDH1A1SMN1; SMN2GAACCR1 | |
| SCHEMBL20601371 | 0.91 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2GAACCR1 | |
| SCHEMBL20601494 | 0.91 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2GAACCR1 | |
| SCHEMBL20601299 | 0.90 | KDM4E (0.50) | KDM4ESMN1; SMN2GAACCR1ITGB3 | |
| SCHEMBL20601214 | 0.90 | TSHR (0.51) | KDM4EALDH1A1GAATSHRCCR1 | |
| SCHEMBL20601521 | 0.90 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2GAACCR1 | |
| SCHEMBL23111244 | 0.89 | KDM4E (0.51) | KDM4EGAACCR1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| WO-2019003142-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | KDM4E 657/4885ALDH1A1 816/4885SMN1; SMN2 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.